ATE249242T1 - Kombinationstherapie von angiotensin- konvertierendem enzym hemmer und epoxy- steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen - Google Patents

Kombinationstherapie von angiotensin- konvertierendem enzym hemmer und epoxy- steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen

Info

Publication number
ATE249242T1
ATE249242T1 AT00912174T AT00912174T ATE249242T1 AT E249242 T1 ATE249242 T1 AT E249242T1 AT 00912174 T AT00912174 T AT 00912174T AT 00912174 T AT00912174 T AT 00912174T AT E249242 T1 ATE249242 T1 AT E249242T1
Authority
AT
Austria
Prior art keywords
epoxy
treatment
combination therapy
cardiovascular diseases
converting enzyme
Prior art date
Application number
AT00912174T
Other languages
English (en)
Inventor
John C Alexander
Barbara Roniker
Subhash Desai
Original Assignee
Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle Llc filed Critical Searle Llc
Application granted granted Critical
Publication of ATE249242T1 publication Critical patent/ATE249242T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT00912174T 1999-03-05 2000-03-03 Kombinationstherapie von angiotensin- konvertierendem enzym hemmer und epoxy- steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen ATE249242T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12297799P 1999-03-05 1999-03-05
PCT/US2000/005633 WO2000051642A1 (en) 1999-03-05 2000-03-03 Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease

Publications (1)

Publication Number Publication Date
ATE249242T1 true ATE249242T1 (de) 2003-09-15

Family

ID=22406014

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03019610T ATE310537T1 (de) 1999-03-05 2000-03-03 Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen
AT00912174T ATE249242T1 (de) 1999-03-05 2000-03-03 Kombinationstherapie von angiotensin- konvertierendem enzym hemmer und epoxy- steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03019610T ATE310537T1 (de) 1999-03-05 2000-03-03 Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen

Country Status (24)

Country Link
US (1) US20040077611A1 (de)
EP (2) EP1165136B1 (de)
JP (1) JP2002538172A (de)
KR (1) KR100580286B1 (de)
CN (1) CN1229141C (de)
AR (1) AR029155A1 (de)
AT (2) ATE310537T1 (de)
AU (2) AU778559B2 (de)
BR (1) BR0008781A (de)
CA (1) CA2364169A1 (de)
DE (2) DE60024335T2 (de)
DK (2) DK1382351T3 (de)
EA (1) EA004064B1 (de)
ES (2) ES2206204T3 (de)
HK (1) HK1042252B (de)
HU (1) HUP0200519A2 (de)
IL (2) IL145237A0 (de)
MX (1) MXPA01009035A (de)
NZ (1) NZ514205A (de)
PT (1) PT1165136E (de)
SI (1) SI1165136T1 (de)
TR (1) TR200102581T2 (de)
WO (1) WO2000051642A1 (de)
ZA (1) ZA200107779B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008449B1 (ru) * 1999-12-08 2007-06-29 Фармация Корпорейшн Кристаллическая форма эплеренона
EP1580193A3 (de) * 1999-12-08 2010-06-23 Pharmacia Corporation Kristalline Form von Eplerenon
EP1505072A3 (de) * 1999-12-08 2006-06-21 Pharmacia Corporation Kristalline Form von Eplerenon mit verbesserter Lösegeschwindigkeit
JP2003516414A (ja) * 1999-12-08 2003-05-13 ファルマシア コーポレイション より高い溶解速度を示すエプレレノン結晶形
AU2001255730A1 (en) * 2000-04-26 2001-11-07 First Horizon Pharmaceutical Corporation Methods and compositions for the treatment of cardiac indications
DK1313485T3 (da) * 2000-08-28 2005-12-27 Pharmacia Corp Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20070112593A1 (en) * 2005-11-14 2007-05-17 Rxcera Pharmaceutical, Inc. Selection system, dispensing system and treatment with a one-a-day combination pill for hypertension, hypercholesterolemia, hypertriglyceridemia and anti-platelet treatment
US20100318371A1 (en) * 2009-06-11 2010-12-16 Halliburton Energy Services, Inc. Comprehensive hazard evaluation system and method for chemicals and products
EP2877579B1 (de) * 2012-07-27 2019-12-18 Ionis Pharmaceuticals, Inc. Modulation von mit dem reninangiotensinsystem (ras) assoziierten erkrankungen durch angiotensinogen
CN106267147A (zh) * 2015-06-10 2017-01-04 上药东英（江苏）药业有限公司 一种复方降压药物组合物
JP2018530325A (ja) 2015-10-08 2018-10-18 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． アンジオテンシノーゲンの発現を調節するための化合物及び方法
MX2023005736A (es) 2020-11-18 2023-05-25 Ionis Pharmaceuticals Inc Compuestos y metodos para modular la expresion de angiotensinogeno.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100618466B1 (ko) * 1995-06-07 2006-12-13 지.디. 썰 엘엘씨 울혈성심마비의치료를위한에폭시-스테로이드계알도스테론길항제및앤지오탠신ii길항제복합요법
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist

Also Published As

Publication number Publication date
SI1165136T1 (en) 2004-02-29
HUP0200519A2 (hu) 2002-07-29
AU2005201045A1 (en) 2005-04-07
BR0008781A (pt) 2002-07-02
AU3394500A (en) 2000-09-21
ZA200107779B (en) 2002-12-20
CN1372475A (zh) 2002-10-02
EP1165136B1 (de) 2003-09-10
KR100580286B1 (ko) 2006-05-16
IL145237A0 (en) 2002-06-30
DE60024335D1 (de) 2005-12-29
CA2364169A1 (en) 2000-09-08
AU778559B2 (en) 2004-12-09
HK1042252B (en) 2004-04-23
EA004064B1 (ru) 2003-12-25
KR20010108319A (ko) 2001-12-07
EP1382351B8 (de) 2006-03-08
IL145237A (en) 2006-08-01
ATE310537T1 (de) 2005-12-15
EA200100951A1 (ru) 2002-04-25
EP1382351A1 (de) 2004-01-21
US20040077611A1 (en) 2004-04-22
DK1165136T3 (da) 2004-01-12
TR200102581T2 (tr) 2002-04-22
EP1382351B1 (de) 2005-11-23
DE60005159D1 (de) 2003-10-16
AR029155A1 (es) 2003-06-18
PT1165136E (pt) 2004-02-27
DE60005159T2 (de) 2004-07-22
NZ514205A (en) 2004-07-30
HK1042252A1 (en) 2002-08-09
MXPA01009035A (es) 2004-08-12
DK1382351T3 (da) 2006-01-23
ES2250803T3 (es) 2006-04-16
EP1165136A1 (de) 2002-01-02
JP2002538172A (ja) 2002-11-12
DE60024335T2 (de) 2006-08-03
ES2206204T3 (es) 2004-05-16
HK1061200A1 (en) 2004-09-10
WO2000051642A1 (en) 2000-09-08
CN1229141C (zh) 2005-11-30

Similar Documents

Publication Publication Date Title
ATE249242T1 (de) Kombinationstherapie von angiotensin- konvertierendem enzym hemmer und epoxy- steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE60324777D1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
ATE369851T1 (de) Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
DE60020100D1 (de) Dimerverbindungen und als inhibitoren der neuramidinase
EP1572116A4 (de) Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
DE60036968D1 (de) Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen
ATE209047T1 (de) Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
ATE357440T1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
DE60221569D1 (de) Acrylsulfonamidderivate zur verwendung als ccr3-antagonisten bei der behandlung von inflammatorischen und immunologischen erkrankungen
ATE374204T1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
NO20030761D0 (no) Farmasöytisk kombinasjon av angiotensin II antagonister og angiotensin I konverterende enzyminhibitorer
ATE385789T1 (de) Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
HRP20050572A2 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
DE60122898D1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
ATE236653T1 (de) Kombination in feste dosiermenge von angiotensin- converting-enzyme-hemmern mit calcium-kanal antagonisten zur behandlung von herz- kreislauferkrankungen
DE60203878D1 (de) Verfahren zur vorbeugung gegen und behandlung von unterleibsschmerzen und magen-darmerkrankungen
ATE295724T1 (de) Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
DE60215060D1 (de) Kräuterpräparat zur behandlung von herz-kreislauf- sowie neurologischen erkrankungen
BR9607612A (pt) Terapia de combinaç o de inibidor de enzima de conversão de angiotensina quantidade de reduzido efeito colateral de antagonista da aldosterona e diurético par tratamento de doenças cardiovasculares

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165136

Country of ref document: EP

REN Ceased due to non-payment of the annual fee